South Africa’s new National Strategic Plan for HIV, TB, and STIs is being developed this year. Spotlight editor Marcus Low asks what we should aim for in the new strategy and how we should go about developing it.
Wieda Human, Ingrid Schoeman, Ruvandhi Nathavitharana, Helene-Mari van der Westhuizen, and Ananja van der Westhuizen from TB Proof argue that we need to look upstream for solutions to improve indoor air quality.
Since the COVID-19 pandemic has stymied the progress of the tuberculosis response across the world, the call for increased investment is important. Although health programmes can always do with more financial assistance, in South Africa, for its TB Recovery Plan to work, the focus should be on the strategic use of existing resources, argues Russell Rensburg.
Professor Keertan Dheda has come a long way from growing up as one of three siblings in a one-bedroom apartment in a high-rise in central Durban. Biénne Huisman chatted to Dheda, now the head of the University of Cape Town’s Division of Pulmonology, and a Professor in Mycobacteriology and Global Health at the London School of Hygiene and Tropical Medicine, about work-life balance, problem-solving that excites him, and a career dedicated to the fight against tuberculosis.
The period covered by South Africa’s National Strategic Plan (NSP) for HIV, TB, and STIs 2017 – 2022 will soon come to an end. Against the backdrop of another World TB Day, Tiyese Jeranji asked several local tuberculosis experts what they think the TB priorities should be as South Africa develops an NSP for the next five years.
Long-acting injections have been successfully used as contraception and more recently HIV prevention. Now researchers are exploring whether similar long-acting injections could be used for the prevention and treatment of tuberculosis. Tiyese Jeranji reports.
Investing in tuberculosis means that everyone has a stake in eliminating TB as a public health threat in our country: every person, every family, every community, every organisation (public and private) as well as government, writes Dr Yogan Pillay and Gaurang Tanna.
While there are nine experimental tuberculosis (TB) vaccines in advanced trials, the vaccine pipeline beyond those nine prospects is relatively depleted. Adele Baleta reports on this and much more from the virtual Global TB Vaccine Forum held last week.
Whether it is in the queue outside a community healthcare clinic, in a GP’s waiting room, or in the ICU at a private sector hospital, infections acquired at healthcare facilities pose a threat to people’s health. Nthusang Lefafa looks at government’s recently relaunched infection prevention and control plans and some obstacles to its implementation.
It wasn’t rocket science when we predicted at the start of 2021 that South Africa’s biggest challenge this year would be to get COVID-19 shots into as many arms as possible. But the way it has played out with multiple setbacks and scrambling problem-solving is not something anyone could have predicted. In fewer than a thousand words, Spotlight editor Marcus Low takes a look back at a tumultuous year in health in South Africa.
The COVID-19 pandemic and associated lockdowns have dealt a severe blow to South Africa’s tuberculosis (TB) response. Tiyese Jeranji asked government about its plans to get TB diagnosis, treatment, and prevention services back on track.
Tuberculosis (TB) preventive therapy is highly effective in preventing TB disease and death, yet only a few people have access to it. Tiyese Jeranji reports on how Médecins Sans Frontières (MSF) in Khayelitsha is helping TB patients, as well as their contacts, access preventive therapy in the comfort of their homes as part of a new family-centred TB care initiative.
